Cryoport, Inc., a provider of temperature-controlled supply chain solutions for the life sciences, has acquired Cell&Co BioServices, headquartered in Clermont-Ferrand, France with additional operations in Pont-du-Château, France. Cell&Co is a bioservices business providing biorepository, kitting, and logistics services to the life sciences industry. Its accreditations include ISO 9001, ANSM (Investigational Medicinal Products), NFS 96 900, and soon, ISO 20387. Supporting its biostorage and services of clinical and commercial biopharma therapies, Cell&Co has in-house QP services.
 
In 2021, Cell&Co recorded revenue of approximately €2.6 million. Cryoport’s purchased Cell&Co for €6.2 million, comprised of upfront consideration of €3.6 million in cash and Cryoport common stock, plus a potential earn-out of €2.5 million based on achieving certain financial targets.
 
Jerrell Shelton, Chief Executive Officer of Cryoport, said, “We are indeed pleased to have the Cell&Co team as a part of Cryoport. Cell&Co will play a significant role in Cryoport Systems’ development of its Global Supply Chain Network, designed to meet the needs of the growing Regenerative Medicine industry worldwide.  In fact, on a global basis, industry experts expect that between now and 2027 approximately 30 to 50 new cell and gene therapies will be introduced into the market each year. Cell&Co’s competencies combined with its location in the centre of France makes it an excellent strategic fit for Cryoport Systems and will accelerate the expansion of its new Global Supply Chain Network by approximately two years.”
 
 “Coupled with our new Global Supply Chain Centers in Houston, Texas and Morris Plains, NJ, Cell&Co will add significantly to the development of Cryoport Systems’ global service offering. It will also provide Cryoport Systems with an EU site for importation services for non-EU clients, which will add significant value for our clients and create additional opportunities for U.S. based regenerative medicine developers looking to conduct clinical trials or commercially distribute cell and gene therapies in EMEA,” added Shelton.